U.S. Food & Drug Administration (FDA) Daily Digest Bulletin

You have requested to receive a Daily Digest e-mail from U.S. Food & Drug Administration (FDA).

Message: 1
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Tue, 4 Mar 2008 06:33:35 -0600 (CST)
Subject: CDRH New Update

	FDA Home Page | CDRH Home Page | Search | A-Z Index

Date: March 4, 2008

The following new items were added to the CDRH web pages on March 3, 2008. Previous CDRH New Items can be found on the CDRHNew Page.

	Expedited Review of Premarket Submissions for Devices - Guidance for Industry and FDA Staff
	Radiological Devices Panel Advisory Meeting, March 4-5, 2008 - Agenda, Roster, Draft Questions

---

Message: 2
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Tue, 4 Mar 2008 09:11:34 -0600 (CST)
Subject: MedWatch - Tamiflu (oseltamivir) associated with neuropsychiatric events, including delirium and abnormal behavior leading to injury

Roche and FDA informed healthcare professionals of neuropsychiatric events associated with the use of Tamiflu, in patients with influenza. These symptoms, as described in post marketing reports mostly from Japan, include delirium and abnormal behavior leading to injury, and in some cases resulting in fatal outcomes. These events were reported primarily among pediatric patients and often had an abrupt onset and rapid resolution. Patients with influenza should be closely monitored for signs of abnormal behavior. If neuropsychiatric symptoms occur, the risks and benefits of continuing treatment should be evaluated.

See the MedWatch 2008 safety summary, including links to the Dear Healthcare Professional letter and Tamiflu Prescribing Information, at:
http://www.fda.gov/medwatch/safety/2008/safety08.htm#Tamiflu

 

---

Message: 3
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Tue, 4 Mar 2008 14:51:20 -0600 (CST)
Subject: FDA MedWatch -Aspire36 and Aspire Lite -Nationwide Recall Of Dietary Supplements Because Products Contained an Analog Of Sildenafil

Palo Alto Labs and FDA notified consumers and healthcare professionals of a voluntary nationwide recall of two dietary supplements, Aspire36 and Aspire Lite. The products were recalled because they were found to contain Aildenafil in trace amounts and Dimethyl sildenafil thione, an analog of Sildenafil, a drug used to treat erectile dysfunction. The presence of these ingredients in the dietary supplements may pose a threat to consumers because the analogue may interact with nitrates found in some prescription drugs (such as nitroglycerin) and may lower blood pressure to dangerous levels. Consumers who have Aspire36 and Aspire Lite in their possession should stop using the products and return any unused product to the place of purchase.

Read the complete 2008 MedWatch Safety Summary, including a link to the manufacturer's press release regarding this issue:

http://www.fda.gov/medwatch/safety/2008/safety08.htm#Aspire

 

 

 

 

---

Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@govdelivery.com.

This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420